Abstract
IntroductionThis study aimed to assess data relevancy and data quality of the Innovation in Medical Evidence Development and Surveillance System Distributed Database (IMEDS-DD) for diabetes research and to evaluate comparability of its type 2 diabetes cohort to the general type 2 diabetes population.Research design and methodsA retrospective study was conducted using the IMEDS-DD. Eligible members were adults with a medical encounter between April 1, 2018 and March 31, 2019 (index period). Type 2 diabetes and co-existing conditions were determined using all data available from April 1, 2016 to the most recent encounter within the index period. Type 2 diabetes patient characteristics, comorbidities and hemoglobin A1c(HbA1c) values were summarized and compared with those reported in national benchmarks and literature.ResultsType 2 diabetes prevalence was 12.6% in the IMEDS-DD. Of 4 14 672 patients with type 2 diabetes, 52.8% were male, and the mean age was 65.0 (SD 13.3) years. Common comorbidities included hypertension (84.5%), hyperlipidemia (82.8%), obesity (45.3%), and cardiovascular disease (44.7%). Moderate-to-severe chronic kidney disease was observed in 20.2% patients. The most commonly used antihyperglycemic agents included metformin (35.7%), sulfonylureas (14.8%), and insulin (9.9%). Less than one-half (48.9%) had an HbA1cvalue recorded. These findings demonstrated the notable similarity in patient characteristics between type 2 diabetes populations identified within the IMEDS-DD and other large databases.ConclusionsDespite the limitations related to HbA1cdata, our findings indicate that the IMEDS-DD contains robust information on key data elements to conduct pharmacoepidemiological studies in diabetes, including member demographic and clinical characteristics and health services utilization.
Funder
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ USA, in collaboration with Pfizer Inc., New York, NY, USA
Subject
Endocrinology, Diabetes and Metabolism
Reference24 articles.
1. The U.S. Food and Drug Administration’s Mini-Sentinel program: status and direction;Platt;Pharmacoepidemiol Drug Saf,2012
2. Developing the Sentinel System — A National Resource for Evidence Development
3. A policy framework for public health uses of electronic health data;McGraw;Pharmacoepidemiol Drug Saf,2012
4. Rosati K , Jorgensen N , Plc CB . Sentinel Initiative Principles and Policies: HIPAA and Common Rule Compliance in the Sentinel Initiative [Internet]. Available: https://www.sentinelinitiative.org/sites/default/files/communications/publications-presentations/HIPAA-Common-Rule-Compliance-in-Sentinel-Initiative.pdf [Accessed 29 Jun 2021].
5. Sentinel Operations Center . Sentinel Common Data Model [Internet]. Available: https://www.sentinelinitiative.org/methods-data-tools/sentinel-common-data-model/sentinel-common-data-model [Accessed 22 Jul 2021].